European Psychiatry
June 1, 2026
J. B. French, J. Kar, B. R. Carr
Introduction The psychiatric incorporation of mindfulness has advanced without a parallel precision in definition. Within both clinical and lay discourse, mindfulness is often conflated with meditation broadly, or with forms of contemplation oriented toward ethical or spiritual ends. This conceptual slippage obscures distinct phenomenological structures and risks importing unexamined...
European Psychiatry
June 1, 2026
Sofia von Humboldt, Isabel Leal
Introduction Meditation may serve as a protective factor for mental well-being in older adults, helping them cope with the ongoing challenges of chronic illness. Objectives The objectives are to: 1) explore the emotional experiences of meditation among older adults living with chronic diseases, and 2) examine the impact of meditation on their mental health. Methods The study involved 426...
BJPsych Open
June 1, 2026
Gayathri Rangith
Aims: Dissociative fugue is a rare dissociative disorder characterised by sudden, reversible loss of autobiographical memory, identity disturbance, and purposeful wandering, often precipitated by acute psychological stress. Due to its infrequency and overlapping presentation with psychosis, delirium, and substance-induced amnesia, dissociative fugue is frequently misdiagnosed. We present a case...
European Psychiatry
June 1, 2026
O. Płaza, Robert Madejek, M. M. Dutsch-Wicherek et al.
Introduction Treatment-resistant depression (TRD), which affects about 30% of patients with major depressive disorder, emerges when patients do not respond adequately to at least two antidepressant trials of proper dose and duration. The EMA approved esketamine nasal spray, the first registered psychedelic medication, in 2019 for TRD treatment. In July 2023, Poland launched B.147, the country’s...
BJPsych Open
June 1, 2026
Rebecca Mcknight, Shanthi Sarma
Aims: Treatment-resistant depression (TRD) is common and associated with substantial disability and economic burden. It is estimated to affect over 100 million people worldwide and approximately 2.7 million people in the United Kingdom. Ketamine has emerged as a novel therapy for TRD, with studies demonstrating rapid antidepressant effects. However, ketamine is also used recreationally and can...
Journal of Consciousness Studies
June 1, 2026
Michael Huemer
Non-reductive functionalism holds that qualia are distinct, non-physical properties that are caused by functional properties. This view violates the plausible principles that (i) mere dispositional properties lack independent causal relevance, and (ii) convention-dependent properties lack causal relevance. David Chalmers’ main arguments for the view rest on his dancing qualia and fading qualia...
European Psychiatry
June 1, 2026
A. M. Matas Ochoa, A. R. Quiroga, I. D. Sacristán
Introduction Psychedelics are hallucinogenic agents that are awakening scientific interest in recent years, especially in the field of mental health. Psychedelics induce non-ordinary states of consciousness and alterations in the emotions and in cognition and could be beneficial in treating some mental illness. Objectives The objective of the poster is to expand knowledge about emerging...
European Psychiatry
June 1, 2026
E. Peters, A. Al Hasani, K. Shukla et al.
Introduction Ketamine therapy for treatment-resistant depression has a well-established rapid antidepressant effect for acute symptom management. However, there is far less research on the efficacy of long-term maintenance therapy for relapse prevention. Objectives To examine the utility of long-term maintenance therapy with ketamine infusions delivered in a naturalistic treatment setting....
European Psychiatry
June 1, 2026
D. Nutt
Abstract The last decade has seen a remarkable resurgence of interest in psychedelic drugs such as psilocybin (from magic mushrooms) LSD and DMT (dimethyl tryptamine – the active ingredient of ayahuasca). This has been driven by the discovery that these psychedelics all act agonists of 5-HT2A receptors plus human imaging studies that reveal this action leads to profound alterations in brain...
European Psychiatry
June 1, 2026
W. Aldulaimy, A. Shah
Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...